Public Companies
Billionaire Investor Steve Cohen Buys 19 million Shares of Cybin
Renowned billionaire investor Steve Cohen has purchased almost 19 million shares of Cybin.
The post Billionaire Investor Steve Cohen Buys 19 million Shares…
Renowned billionaire investor Steve Cohen has purchased almost 19 million shares of Cybin.
According to a September 14th SEC filing, Cohen’s hedge fund Point72 Asset Management purchased 18,950,000 shares of Cybin (NYSE-A:CYBN, NEO:CYBN) — representing an approximate 8.1% stake in Cybin.
Cohen is a well-known biotech investor, investing in firms focused on developing new therapeutic and drug compounds. He has also supported psychedelic research in the past with major donations to MAPS.
This large investment through his hedge fund, however, moves his support from personal to the professional, signaling to mainstream institutional investors that psychedelic medicine may be worth a serious closer look. It not only adds credibility to the sector’s investment thesis but shows that Cybin, after its recent acquisition of Small Pharma, might be a firm with a very interesting value proposition for investors.
Cybin’s stock was up almost 20% today on the news.
The post Billionaire Investor Steve Cohen Buys 19 million Shares of Cybin appeared first on Microdose.
psychedelic investing investors shares fund cybin small pharma research
-
Psychedelics1 week agoRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics1 week agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week agoTryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week agoSilo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week agoPsilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness